New drug mimics natural protein to calm overactive immune system in nerve disease
Disease control
Ongoing
This Phase 2 trial is testing a new drug called NVG-2089 in 60 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system attacks nerves. The drug is designed to mimic a natural protein (IVIg) to reduce inflammation and improve nerve…
Phase: PHASE2 • Sponsor: Nuvig Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC